An impressive response to pazopanib in a patient with metastatic endometrial carcinoma.
作者信息
van der Steen M J, de Waal Y R P, Westermann A, Tops B, Leenders W, Ottevanger P B
机构信息
First auteur: Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands Second auteur: Gynaecological Oncology, Amsterdam Medical Centre, Amsterdam, the Netherlands.
出版信息
Neth J Med. 2016 Nov;74(9):410-413.
The incidence of endometrial carcinoma is rising and the patients with distant metastases have a poor prognosis, especially when progression of disease occurs after systemic treatment with hormonal therapy or chemotherapy. Pazopanib, a multi-targeted inhibitor of several oncogenic receptor tyrosine kinases, has been investigated in patients with chemotherapy-resistant endometrial carcinoma or patients for whom chemotherapy is contraindicated. In this report we will describe a spectacular response to pazopanib in a patient with recurrent metastatic endometrial carcinoma.
Zotero 插件